Three specialists discuss unmet medical needs in neuropathic pain, and share expert guidance that could improve clinical outcomes for these patients.
Unmet needs and recent advances in the management of neuropathic pain
Dr Bouhassira listed that he is/was a consultant/advisor for Bayer AG and Grünenthal B.V.. He listed as well that the is/was research grant recipient from Bayer AG, Grünenthal B.V., and Novartis.
Dr Dickenson listed that he was a speaker on a speaker's bureau for Grünenthal UK and Portugal.
Dr Freeman listed that he is/was a consultant/advisor for AlgoRx, Allergan, Clexio, Collegium, Glenmark, GW Pharma, Glaxo-Smith Kline, Eli Lilly, Lundbeck, Maxona, Novartis, Vertex, and Worwag. He listed stock ownership from Applied Therapeutics, Cutaneous NeuroDiagnostics, NeuroBo, and Regenacy.